1469 / 1674
The risk of late morbidity is a key factor in the planning and decision
making of how and when RT should be used in breast cancer
treatment
This is because RT is adjuvant, and we do not see on the patient the
“anti-tumor effect” due to the late occurrence and low frequency of
loco-regional failure in irradiated patients
In the multimodal practice, (late) radiation morbidity therefore is our
guidance – and indications for RT, target volume (incl. partial breast
irradiation), chemo-RT sequence etc. are all decisions which are
largely “morbidity driven”
Knowledge of morbidity and its underlying mechanisms is therefore of
utmost importance
Something about breast RT morbidity